Cara Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference

Rhea-AI Summary

Cara Therapeutics, Inc. (Nasdaq: CARA) announced that CEO Derek Chalmers will participate in a fireside chat at the Canaccord Genuity 40th Annual Growth Conference on August 13, 2020, at 8:00 a.m. ET. The event will be accessible via a live webcast on the company's website, with an archived recording available for 30 days. Cara is focused on developing new chemical entities for pruritus treatment, particularly KORSUVA (CR845/difelikefalin), which has shown promise in clinical trials for patients with chronic kidney disease-associated pruritus.

STAMFORD, Conn., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020 at 8:00 a.m. ET.

A live webcast of the presentation can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). Cara has successfully completed its Phase 2 trial of Oral KORSUVA for the treatment of pruritus in patients with CKD and is currently conducting Phase 2 trials of Oral KORSUVA in atopic dermatitis and primary biliary cholangitis patients with moderate-to-severe pruritus.

The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

INVESTOR CONTACT:
Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com

MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com

FAQ

When is the Canaccord Genuity 40th Annual Growth Conference where CARA's CEO will speak?

The Canaccord Genuity 40th Annual Growth Conference will take place on August 13, 2020, at 8:00 a.m. ET.

How can I watch the CARA CEO's presentation at the conference?

You can watch the presentation live through a webcast available on Cara Therapeutics' website under 'Events & Presentations.'

What is KORSUVA, the focus of Cara Therapeutics?

KORSUVA (CR845/difelikefalin) is a first-in-class kappa opioid receptor agonist aimed at alleviating pruritus in patients with chronic kidney disease.

What results did KORSUVA show in clinical trials?

KORSUVA Injection demonstrated significant reductions in itch intensity and improved quality of life in moderate-to-severe chronic kidney disease-associated pruritus patients.

Is KORSUVA FDA approved?

KORSUVA has conditionally been accepted as the trade name for difelikefalin injection, but its safety and efficacy have not been fully evaluated by the FDA.